Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.



Pre-eclampsia is a multisystem disease unique to pregnancy. At our company, we are dedicated to advancing the forefront of pre-eclampsia management through state-of-the-art diagnostics and therapeutics. As your trusted ally in pre-eclampsia research, we provide efficient and all-encompassing solutions to cater to your every scientific research need.

Introduction to Pre-eclampsia

Pre-eclampsia is a multifaceted and potentially perilous disorder that impacts pregnant individuals. It manifests through the emergence of elevated blood pressure and the detection of protein in the urine after 20 weeks of pregnancy. This condition poses substantial hazards to both the mother and the developing fetus, underscoring the urgent need for timely medical intervention and comprehensive care. Pre-eclampsia affects approximately 2-8% of pregnancies worldwide and is one of the common causes of pregnancy.

Pathological mechanisms and characteristic manifestations of pre-eclampsia.Fig. 1 Pathogenesis of pre-eclampsia. (Ives, Christopher W., et al., 2020)

Pathogenesis of Pre-eclampsia

The exact cause of pre-eclampsia remains elusive, and its pathogenesis is multifactorial, involving intricate interactions between the placenta, maternal immune system, and vascular dysfunction. In addition, pre-eclampsia may be related to genetic and environmental factors.

Placental Factors

Placental Factors

There is evidence that placental perfusion is impaired in pre-eclampsia, resulting in reduced blood flow to the placenta, which can lead to the release of various factors that trigger pre-eclampsia.

Angiogenic Imbalance

Angiogenic Imbalance

Pre-eclampsia is associated with decreased levels of pro-angiogenic factors and increased levels of anti-angiogenic factors. This dysregulation disrupts normal vascular development and function, leading to endothelial dysfunction and the characteristic manifestations of pre-eclampsia.

Maternal Immune Response

Maternal Immune Response

Exaggerated maternal immune response to the presence of paternal antigens in the placenta triggers inflammation and oxidative stress, further compromising vascular function and contributing to the systemic manifestations of pre-eclampsia.

Types of Pre-eclampsia Therapy

Targeted Therapy

Biologics and targeted therapies are designed to specifically target the underlying mechanisms of pre-eclampsia. For example, sFlt-1 is an anti-angiogenic factor that plays an important role in the pathogenesis of pre-eclampsia. Researchers are exploring the use of sFlt-1 blockers, such as soluble receptors or monoclonal antibodies, to counteract its effects.

Gene Therapy

Gene therapy is an emerging field with the potential to revolutionize the therapeutics of various diseases. Gene therapy has the potential to reduce the risk or severity of the condition by targeting specific genetic variants associated with susceptibility to pre-eclampsia. However, gene therapy for pre-eclampsia is still in the early stages of development and requires further research.

Our Services

With years of extensive involvement in rare disease research, our company boasts a highly skilled team and vast expertise. We harness state-of-the-art technology to drive the development of innovative diagnostic tools, enabling early detection of pre-eclampsia. By establishing animal models and conducting in-depth investigations into pre-eclampsia pathogenesis and targets, we advance therapeutic drug development.

Our Research Platforms

Our Services

Animal Models of Pre-eclampsia

Induced Models
Our company specializes in the use of biological and chemical agents to induce characteristics associated with pre-eclampsia in animals. For example, our scientists administered L-NAME (Nω-nitro-L-arginine methyl ester) to animals to induce hypertension and endothelial dysfunction. Additionally, we administer immune stimulants such as lipopolysaccharides or proinflammatory cytokines to trigger an immune response that mimics the inflammatory component of pre-eclampsia.
Genetically Engineered Models
We use advanced transgenic and knockout technologies to genetically modify specific genes involved in pre-eclampsia. By introducing or deleting specific genes, our researchers can study the impact of these genetic changes on the development of pre-eclampsia symptoms.
Optional Models
  • BPH/5 Model
  • Angiotensinogen/Renin Overexpression Model
  • STOX1 Overexpression Model
  • Asb4−/− Model
  • ELABELA Knockout Model
  • C1q−/− Model
  • Dahl S Model
Reduced Uterine Perfusion Pressure (RUPP) Models
RUPP models involve the surgical reduction of uterine perfusion pressure, leading to placental ischemia and subsequent development of pre-eclampsia-like features. These models mimic the placental insufficiency seen in pre-eclampsia, resulting in hypertension, proteinuria, and impaired fetal growth. RUPP models offer a valuable tool for studying the vascular and placental aspects of pre-eclampsia.
Optional Species Mice, Rats, Non-Human Primates (Baboons or Macaques), Others

No matter what stage of research you are at, we can provide you with corresponding research services. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Ives, Christopher W., et al. "Preeclampsia—pathophysiology and clinical presentations: JACC state-of-the-art review." Journal of the American College of Cardiology 76.14 (2020): 1690-1702.
  • Bakrania, Bhavisha A., Eric M. George, and Joey P. Granger. "Animal models of preeclampsia: investigating pathophysiology and therapeutic targets." American journal of obstetrics and gynecology 226.2 (2022): S973-S987.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.